Aarkstore - Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0ebe-OWY5O



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Interleukin-2 (IL-2) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Interleukin-2 (IL-2) Inhibitors. – PowerPoint PPT presentation

Number of Views:10

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Interleukin-2 (IL-2) Inhibitors -Pipeline Insights, 2014


1
Interleukin-2 (IL-2) Inhibitors -Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/75779/interleukin-2-il-2-inhibitors-pipeline-ins
    ights-2014

2
Summary
  • DelveInsights,Interleukin-2 (IL-2)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Interleukin-2 (IL-2) Inhibitors. This
    report provides information on the therapeutic
    development based on the Interleukin-2 (IL-2)
    Inhibitors dealing with mechanism of action,
    comparative analysis at various stages covering
    Filed, Phase III, Phase II, Phase I, IND filed,
    Preclinical, Discovery and unknown stages,
    therapeutics assessment by monotherapy and
    combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts. Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases. Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Interleukin-2 (IL-2)
    Inhibitors The report provides pipeline products
    under drug profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    information Coverage of the Interleukin-2 (IL-2)
    Inhibitors pipeline on the basis of target, MOA,
    route of administration, technology involved and
    molecule type The report reviews key players
    involved in the therapeutics development for
    Interleukin-2 (IL-2) Inhibitors and also provide
    company profiling The report also gives the
    information of dormant and discontinued pipeline
    projects  Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages  Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete MOA intelligence and
    complete understanding over therapeutics
    development for Interleukin-2 (IL-2)
    Inhibitors Identify the relationship between the
    drugs and use it for target finding, drug
    repurposing, and precision medicine. Devise
    corrective measures for pipeline projects by
    understanding Interleukin-2 (IL-2) Inhibitors
    pipeline depth and focus of Indication
    therapeutics  Developing strategic initiatives to
    support your drug development activities. Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope Provides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies  Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipeline Gaining a Full Picture of the
    Competitive Landscape for Evidence based
    Decisions
  • You can order full Report with TOC and for Sample
    page visit _at_
  • http//www.aarkstore.com/pharmaceuticals-healthca
    re/75779/interleukin-2-il-2-inhibitors-pipeline-in
    sights-2014

7
Table of Content
  • Interleukin-2 (IL-2) Inhibitors
    Overview Interleukin-2 (IL-2) Inhibitors Disease
    Associated Interleukin-2 (IL-2) Inhibitors
    Pipeline Therapeutics Interleukin-2 (IL-2)
    Inhibitors Therapeutics under Development by
    Companies  Interleukin-2 (IL-2) Inhibitors Late
    Stage Products (Filed and Phase III) Comparative
    Analysis  Interleukin-2 (IL-2) Inhibitors Mid
    Clinical Stage Products (Phase II) Comparative
    Analysis  Interleukin-2 (IL-2) Inhibitors Early
    Clinical Stage Products (Phase I and IND
    Filed) Comparative Analysis  Interleukin-2 (IL-2)
    Inhibitors Discovery and Pre-Clinical Stage
    Products  Comparative Analysis  Drug Candidate
    Profiles

8
Table of Content
  • Interleukin-2 (IL-2) Inhibitors Therapeutics
    Assessment  Assessment by Monotherapy
    Products  Assessment by Combination
    Products  Assessment by Route of
    Administration  Assessment by Molecule
    Type  Interleukin-2 (IL-2) Inhibitors
    Discontinued Products  Interleukin-2 (IL-2)
    Inhibitors Dormant Products Companies Involved in
    Therapeutics Development for Interleukin-2 (IL-2)
    Inhibitors  Appendix  Methodology  Contact
    Us  Disclaimer

9
List of Tables
  • Number of Products under Development for
    Interleukin-2 (IL-2) Inhibitors by Therapy Area,
    2014 Number of Products under Development for
    Interleukin-2 (IL-2) Inhibitors, 2014 Number of
    Products under Development by Companies  Comparati
    ve Analysis by Late Clinical Stage Products
    (Filed and Phase III), 2014 Comparative Analysis
    Mid Clinical Stage Products (Phase II),
    2014 Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014 Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014 Drug Candidates
    Profiles

10
List of Tables
  • Interleukin-2 (IL-2) Inhibitors Assessment by
    Monotherapy Products  Interleukin-2 (IL-2)
    Inhibitors Assessment by Combination
    Products  Interleukin-2 (IL-2) Inhibitors
    Assessment by Route of Administration  Interleukin
    -2 (IL-2) Inhibitors Assessment by Stage and
    Route of Administration  Interleukin-2 (IL-2)
    Inhibitors Assessment by Molecule
    Type  Interleukin-2 (IL-2) Inhibitors Assessment
    by Stage and Molecule Type  Interleukin-2 (IL-2)
    Inhibitors Therapeutics Discontinued
    Products  Interleukin-2 (IL-2) Inhibitors
    Therapeutics Dormant Products Products under
    Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for
    Interleukin-2 (IL-2) Inhibitors by Therapy Area,
    2014 Number of Products under Development for
    Interleukin-2 (IL-2) Inhibitors, 2014 Late
    Clinical Stage Products (Filed and Phase III),
    2014 Mid Clinical Stage Products (Phase II),
    2014 Early Clinical Stage Products (Phase I and
    IND Filed), 2014 Discovery and Pre-Clinical Stage
    Products, 2014 Interleukin-2 (IL-2) Inhibitors
    Assessment by Monotherapy Products  Interleukin-2
    (IL-2) Inhibitors Assessment by Combination
    Products  Interleukin-2 (IL-2) Inhibitors
    Assessment by Route of Administration  Interleukin
    -2 (IL-2) Inhibitors Assessment by Stage and
    Route of Administration  Interleukin-2 (IL-2)
    Inhibitors Assessment by Molecule
    Type  Interleukin-2 (IL-2) Inhibitors Assessment
    by Stage and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Interleukin-2 (IL-2) Inhibitors -Pipeline
    Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Interleukin-2 (IL-2)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com